Chengdu Easton Biopharmaceuticals Co Ltd

Yuan Dong Bio announced that on July 16, 2026, it received the Drug Registration Certificate for Remimazolam Besylate for Injection approved and issued by the National Medical Products Administration, with a specification of 25 mg, approved under chemical drug category 4, making it the first domestic company to receive approval for this generic drug. The drug is a Class II psychotropic substance, indicated for sedation and anesthesia in non-tracheal intubation procedures or operations, as well as for the induction and maintenance of general anesthesia.

The Sci-Tech Innovation Board Medical ETF Huaxia closed up 2.22% at 1.06 yuan, while the underlying SSE STAR Market Biomedical Index surged 2.38%. Among constituents, Medicilon rose 12.77%, Olymvax Biopharmaceuticals gained 11.54%, and YD Bio advanced 8.49%. Recent policy tailwinds continue to unfold, including optimized review and approval for cell and gene therapies and the initial inclusion of drugs in medical insurance and commercial insurance catalogues. Meanwhile, domestic innovative drug overseas licensing deals approached 100 billion US dollars in the first half of the year, blockbuster new drugs received intensive approvals, and some pharmaceutical companies reported positive half-year earnings forecasts, steadily improving industry fundamentals. Donghai Securities noted that the pharmaceutical and biomedical sector offers significant medium- to long-term investment value and recommended active positioning.

The STAR Market Healthcare ETF Huaxia rose 3.86% to 1.08 yuan, with net inflows for 10 consecutive days, attracting a total of 135 million yuan. The SSE STAR Market Biomedical Index surged 3.93%, with constituent stocks Medici rising 15.28%, Yundong Biotech up 11.44%, and Olin Biotech up 10.38%. In news, the National Essential Medicines List 2026 edition added 165 new drugs, and in the first half of 2026, the total value of China's innovative drug out-licensing deals approached the 100 billion dollar mark. Nanjing Securities noted that with the upcoming WCLC and ESMO conferences, cutting-edge fields such as bispecific antibodies and antibody-drug conjugates will enter a period of intensive clinical data disclosure, accelerating the alignment of China's innovative drug valuation system with global standards.